Drug Discovery Outsourcing: World Market 2013-2023

November 2012 | 157 pages | ID: D7CFDFBE4F5EN
Visiongain

Abstracts

How much revenue can drug discovery outsourcing generate? Our new report shows you

See what the future holds for outsourcing early-stage drug development. There is rising demand for those services. Visiongain's updated report gives you revenue predictions to 2023, showing you data, trends, opportunities and commercial prospects.

Our study is your guide to the potential of those pharmaceutical services. That analysis lets you assess forecasted sales at overall world market, submarket and national level. You see outlooks for the outsourced drug discovery industry and market and its participants.

Forecasts and other analyses to help you find growth opportunities

In our report you find revenue forecasting to 2023, historical data, growth rates and market shares. Also, you see qualitative analysis (SWOT and STEP), business news, outlooks and developmental trends (R&D). You receive 64 tables, 46 charts and two research interviews.

We show where sales growth can occur. You investigate the most lucrative areas of that contract research segment, assessing industry trends, dynamics and outlooks. Its technologies hold great promise for service providers and the pharma industry.

You can stay ahead in knowledge, benefiting your research and analyses. The following sections show what you find in our new study.

You see prospects for the world market and submarkets

Along with analyses of the overall world market, you see revenue forecasting of four outsourcing submarkets at world level. We show data from 2011 to 2023:

• Chemical services
• Biological services
• Lead optimisation
• Lead identification and screening.

With our investigation you gain business research and analysis with individual sales predictions and discussions. You find analysis of competition, as well as commercial drivers and restraints. See what's likely to achieve the most success.

You can win competitive advantages by understanding the trends, opportunities and challenges facing contract research organisations (CROs) in drug discovery.

Our work also breaks the overall world forecast into leading national markets.

What are the prospects in leading regions and countries?

Developments worldwide will influence the market, especially rising demand in emerging countries - China, India and others. There are many opportunities for CRO service providers and pharma clients.

In our study you find individual revenue forecasts to 2023 for eleven national markets:

• US
• Japan
• Germany, France, UK, Italy and Spain (EU5)
• Brazil, Russia, India and China (BRIC nations).

See what's likely to happen. There will be high growth in established markets and developing countries - especially to 2017 - our analyses show. You find areas with highest potential. Also, you investigate reasons for revenue growth.

What issues will affect outsourced drug discovery?

Our report discusses issues and events affecting early-stage drug development from 2012 onwards:

• Progress in target identification, validation, chemistry, biology and ADMET screening
• Cost reductions, outsourcing efficiency and improved turnaround times
• Strategic partnering and differentiation of research activities provision
• Biologics, biosimilars and orphan drug development.

Also, you find coverage of these aspects:

• Regional expansion, competition and CRO consolidation
• Niche CROs and virtual pharmaceutical companies
• Technology transfer and intellectual property (IP)
• Competition from public-private partnerships
• Technological developments - instruments, biomarkers, genomics and proteomics.

See what the future holds. You investigate technological, commercial, economic and political matters, with emphasis on the competitive landscape and business outlooks.

Leading companies and market value in 2015

What will happen next? Overall world revenue for that market area will reach $16.6bn in 2015, our work forecasts. We predict strong revenue growth from 2012 to 2023.

Our study gives you analyses of these CROs:

• Quintiles
• Charles River Laboratories
• Covance
• Evotec
• PPD.

We also give profiles of these service vendors, and discuss other companies too:

• Albany Molecular Research
• Aptuit
• Cyprotex
• Domainex
• Galapagos
• GenScript
• WIL Research Laboratories
• WuXi AppTec.

Also, you see interviews with two companies. You see what's happening. This decade, many opportunities will arise - our report shows you the commercial possibilities.

Seven ways Drug Discovery Outsourcing: World Market 2013-2023 helps you

In particular, then, our investigation gives you the following knowledge on the topic:

• Forecasted revenues to 2023 for the overall world market and 4 submarkets - you discover the industry's future prospects
• Market forecasting to 2023 for US, Japan, Germany, France, UK, Spain, Italy, Brazil, Russia, India and China - you see national sales outlooks
• Profiles of 13 leading companies - you hear about CROs' activities, recent results, strategies and outlooks
• Opinions on the sector - you read our interviews with leaders in industry
• Competition and opportunities influencing sales - you see what affects the future
• Discussions of what stimulates and restrains the industry and market - you assess trends, drivers and restraints
• Prospects for established organisations and those seeking to enter the sector - you see factors and outlooks for success.

Benefit from our analyses, gaining information found nowhere else

That work gives independent analysis from our primary and secondary research. You receive business intelligence found only in our study, seeing where prospects are lucrative and growth is likely.

With our report you are less likely to fall behind in knowledge or miss opportunity. See how our work could benefit your research, analyses and decisions, saving you time and getting you recognition for commercial insight.

You find prospects to 2023 for drug discovery services by ordering now

Visiongain's study is for everyone needing analysis of the industry and market for outsourced drug development. You find data, trends and predictions. Please ask for our report now.

Visiongain is a trading partner with the US Federal Government

Contents

1. EXECUTIVE SUMMARY

1.1 Review of the Global Drug Discovery Outsourcing Market
1.2 Aims, Scope and Format of Report
1.3 Research and Analysis Methods

2. DRUG DISCOVERY OUTSOURCING: AN INTRODUCTION

2.1 Outsourcing in the Pharmaceutical and Biotechnology Industries
  2.1.1 Outsourcing Drug Discovery
2.2 Reasons for Outsourcing Drug Discovery Operations
  2.2.1 Strategic Outsourcing vs. Tactical Outsourcing
  2.2.2 Benefits of Outsourcing
  2.2.3 Cost Pressures and Declining R&D Budgets
  2.2.4 Outsourcing and Focus on Core Competencies
  2.2.5 Outsourcing to Improve Efficiency and Reduce Time-to-Market
  2.2.6 Forming Strategic Partnerships with Big Pharma
2.3 The Drug Discovery Process - What Can be Outsourced?
2.4 A New Model for Drug Development?
2.5 Academic Laboratories - Early Drug Discovery Research
2.6 Quality of Service is Important for CROs
2.7 Drug Discovery Outsourcing by the Pharmaceutical Industry

3. LEADING COMPANIES OFFERING DRUG DISCOVERY SERVICES

3.1 Introduction
3.2 Key Attributes of a Successful Contract Research Organisation (CRO)
  3.2.1 Competitive Cost Structure
  3.2.2 Strong Scientific Skill Set
  3.2.3 Excellent Turnaround Times and Good Communication
  3.2.4 Intellectual Property Security
  3.2.5 Good Working Relationships are Essential
3.3 Drug Discovery Service Providers, 2011
3.4 Albany Molecular Research, Inc (AMRI)
  3.4.1 Drug Discovery at AMRI
  3.4.2 Discovery Collaboration Record
3.5 Aptuit
  3.5.1 Aptuit INDiGO - Accelerated Drug Development Programme
  3.5.2 Strategic Partnership With Laurus Labs
3.6 Charles River Laboratories
  3.6.1 Revenue Analysis 2006-2011
  3.6.2 Early Stage Restructuring
3.7 Covance
  3.7.1 Revenue Analysis 2009-2011
  3.7.2 Refocusing Early-Stage Efforts
  3.7.3 Strategic Alliance Experience
3.8 Cyprotex - ADMET Service Provider
3.9 Domainex - Full Service Drug Discovery Provider
3.10 Evotec - Discovery Alliances and Development Partnerships
  3.10.1 Action Plan 2016 - Leadership in Drug Discovery Solutions
3.11 Galapagos (GLPG)
  3.11.1 Galapagos - Recent Activity
3.12 GenScript
  3.12.1 GenScript - Outsourcing Activity
3.13 PPD - A Leading CRO
  3.13.1 Revenue Analysis 2009-2011
  3.13.2 Strategic Alliances and Private Merger
  3.13.3 Expansion in Asia
  3.13.4 PPD and BioDuro
3.14 Quintiles - Largest Biopharmaceutical Services Company
  3.14.1 Quintiles - Acquisition of Advion Bioanalytical Labs
  3.14.2 Quintiles - New Developments
3.15 WIL Research Laboratories
3.16 WuXi AppTec - A Leading Chinese CRO
  3.16.1 Revenue Analysis 2006-2011
  3.16.2 WuXi's Strategic Partnerships and Other Recent Developments

4. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET 2013-2023

4.1 The Global Drug Discovery Outsourcing Market 2011
4.2 Global Drug Discovery Outsourcing: Market Forecast 2013-2023
4.3 Global Chemistry Services Outsourcing Market 2013-2023
  4.3.1 Global Chemistry Services Outsourcing 2011
    4.3.1.1 Custom Synthesis
    4.3.1.2 Building Blocks
    4.3.1.3 Process Research
    4.3.1.4 Libraries
  4.3.2 Global Chemistry Services Outsourcing: Market Forecast 2013-2023
4.4 Global Biology Services Outsourcing Market 2013-2023
  4.4.1 Global Biology Services Outsourcing 2011
    4.4.1.1 Target Identification
    4.4.1.2 Target Validation
  4.4.2 Global Biology Services Outsourcing: Market Forecast 2013-2023
4.5 Global Lead Optimisation Outsourcing Market 2013-2023
  4.5.1 Global Lead Optimisation Outsourcing 2011
    4.5.1.1 ADMET Screening
  4.5.2 Global Lead Optimisation: Market Forecast 2013-2023
4.6 Global Lead Identification and Screening Outsourcing Market 2013-2023
  4.6.1 Global Lead Identification and Screening Outsourcing 2011
    4.6.1.1Lead Identification
  4.6.2 Global Lead Identification and Screening Outsourcing: Market Forecast 2013-2023

5. LEADING NATIONAL MARKETS FOR DRUG DISCOVERY OUTSOURCING 2013-2023

5.1 Supply and Demand for Drug Discovery Outsourcing Services
5.2 The Drug Discovery Outsourcing Market: Regional Breakdown 2011
5.3 The US Drug Discovery Outsourcing Market Forecast 2013-2023
5.4 Leading Western European (EU5) Countries: Market Forecast 2013-2023
  5.4.1 The German Drug Discovery Outsourcing Market Forecast 2013-2023
  5.4.2 The UK Drug Discovery Outsourcing Market Forecast 2013-2023
  5.4.3 The French Drug Discovery Outsourcing Market Forecast 2013-2023
  5.4.4 The Italian Drug Discovery Outsourcing Market Forecast 2013-2023
  5.4.5 The Spanish Drug Discovery Outsourcing Market Forecast 2013-2023
5.5 The Japanese Drug Discovery Outsourcing Market Forecast 2013-2023
5.6 Emerging BRIC Nations 2013-2023
  5.6.1 BRIC Nations Will Lead Market Growth
  5.6.2 The Brazilian Drug Discovery Outsourcing Market Forecast 2013-2023
  5.6.3 The Russian Drug Discovery Outsourcing Market Forecast 2013-2023
  5.6.4 The Indian Drug Discovery Outsourcing Market Forecast 2013-2023
  5.6.5 The Chinese Drug Discovery Outsourcing Market Forecast 2013-2023

6. DRUG DISCOVERY OUTSOURCING: WORLD MARKET TRENDS 2013-2023

6.1 SWOT Analysis of the Market 2013-2023
  6.1.1 Drivers and Restraints for Drug Discovery Outsourcing 2013-2023
6.2 Market Strengths
  6.2.1 Cost Reductions Will Drive Drug Discovery Operations
  6.2.2 Outsourcing Efficiency Improves Turnaround Times
6.3 Market Weaknesses
  6.3.1 Some CROs Offer Service Ranges Without Clear Market Differentiation
  6.3.2 Adverse Effects of Reducing R&D Spending
6.4 Market Opportunities and Threats
  6.4.1 Trends in Drug Development
  6.4.2 Orphan Drug Development
  6.4.3 Biologics and Biosimilars
  6.4.4 CRO Expansion
    6.4.4.1 An Increasingly Competitive Market
    6.4.4.2 Regional Expansion
  6.4.5 Increased CRO Consolidation and Niche CROs
  6.4.6 Outsourcing Strategy Depends on Company Size
  6.4.7 Virtual Pharmaceutical Companies
  6.4.8 Technology Transfer and Intellectual Property Protection
  6.4.9 Competition from Public-Private Partnerships
  6.4.10 Pharma Resource Sharing Could Restrain CRO Growth
6.5 STEP Analysis for Drug Discovery Outsourcing 2013-2023
  6.5.1 Social Factors
    6.5.1.1 Increased Healthcare Demands
    6.5.1.2 Good Communication is Vital
  6.5.2 Technological Developments
    6.5.2.1 Biomarkers as a Tool for Drug Development
    6.5.2.2 Technological Advances in Genomic and Proteomic Instrumentation
  6.5.3 Economic Pressures
    6.5.3.1 Cutting Back Pharma R&D
    6.5.3.2 Growth in Strategic Partnering
  6.5.4 Political Issues
    6.5.4.1 Quality Practices in Basic Biomedical Research (QPBR) and Good Laboratory Practice (GLP)
    6.5.4.2 Global Harmonisation of Regulatory Policies: The ICH

7. OPINIONS FROM OUR SURVEY: RESEARCH INTERVIEWS

7.1 Interview with Dr Raj (SB) Rajur, Chairman & CEO, CreaGen Biosciences
  7.1.1 Thoughts on Current State of the Market
  7.1.2 Drug Discovery Services at CreaGen Biosciences
  7.1.3 Challenges Facing Pharma and Biotech R&D
  7.1.4 Thoughts on Therapeutic Areas and Niche CROs
  7.1.5 National Markets for Drug Discovery Outsourcing
  7.1.6 Drivers and Restraints for Market Growth
7.2 Interview with Dr Mario Polywka, Chief Operating Officer, Evotec
  7.2.1 CROs and R&D Outsourcing
  7.2.2 Drug Discovery Outsourcing Services
  7.2.3 Thoughts on Drug Discovery Trends
  7.2.4 Driving Drug Discovery Outsourcing

8. CONCLUSIONS

8.1 Robust Growth for Drug Discovery Outsourcing 2013-2023
8.2 Outsourcing in Asia Will Continue to Grow
8.3 Key Indications for Research Will Drive Growth
8.4 Opportunities for Strategic Partnering and Niche CROs Will Continue

List Of Tables

LIST OF TABLES

Table 1.1 Currency Exchange Rates, 2011
Table 2.1 Indication of Functions Outsourced in the Different Stages of the Drug R&D Process, 2012
Table 3.1 AMRI Revenue ($m), 2007-2011
Table 3.2 AMRI Drug Discovery Portfolio, 2012
Table 3.3 Selected Services Provided by Charles River Laboratories, 2012
Table 3.4 Charles River Laboratories Revenue ($bn), 2006-2011
Table 3.5 Charles River Laboratories Revenue ($bn) by Business Segment, 2009-2011
Table 3.6 Covance Revenue ($bn) by Segment, 2009-2011
Table 3.7 Covance Revenue ($bn) by Service, 2009-2011
Table 3.8 Selected Cyprotex Partners, 2012
Table 3.9 Cyprotex Revenue ($m), AGR (%), 2009-2011
Table 3.10 Selected Examples of Domainex's Collaborations
Table 3.11 Evotec Revenue ($m), AGR (%), 2007-2011
Table 3.12 Evotec Alliances, AGR (%), 2008-2011
Table 3.13 Evotec Action Plan 2016 - Leadership in Drug Discovery Solutions
Table 3.14 Galapagos: Selected Pipeline Activity, 2012
Table 3.15 Galapagos Alliances, 2006-2012
Table 3.16 Galapagos Revenues ($m), AGR (%), 2008-2011
Table 3.17 Select GenScript Services, 2012
Table 3.18 PPD Revenue ($bn), 2009-2011
Table 3.19 WuXi AppTec: Pharmaceutical Laboratory Services, 2012
Table 3.20 WuXi AppTec Revenue ($bn), 2006-2011
Table 4.1 Global Drug Discovery Outsourcing Revenue Forecasts by Segment ($m), AGR (%), CAGR (%), 2011-2017
Table 4.2 Global Drug Discovery Outsourcing Revenue Forecasts by Segment ($m), AGR (%), CAGR (%), 2017-2023
Table 4.3 Drug Discovery Outsourcing: World Market Shares by Segment (%), 2011, 2017 & 2023
Table 4.4 Chemistry Services Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 4.5 Chemistry Services Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 4.6 Biology Services Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 4.7 Biology Services Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 4.8 Lead Optimisation Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 4.9 Lead Optimisation Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 4.10 Lead Identification and Screening Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 4.11 Lead Identification and Screening Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 5.1 National Drug Discovery Outsourcing Revenue Forecasts ($m), AGR (%), CAGR (%), 2011-2017
Table 5.2 National Drug Discovery Outsourcing Revenue Forecasts ($m), AGR (%), CAGR (%), 2017-2023
Table 5.3 Drug Discovery Outsourcing: World Market Shares by Region (%), 2011, 2017 & 2023
Table 5.4 The US Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 5.5 The US Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 5.6 EU5 Drug Discovery Outsourcing Revenue Forecasts ($m), AGR (%), CAGR (%), 2011-2017
Table 5.7 EU5 Drug Discovery Outsourcing Revenue Forecasts ($m), AGR (%), CAGR (%), 2017-2023
Table 5.8 Drug Discovery Outsourcing: EU5 Market Shares by Region (%), 2011, 2017 & 2023
Table 5.9 The German Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 5.10 The German Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 5.11 The UK Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 5.12 The UK Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 5.13 The French Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 5.14 The French Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 5.15 The Italian Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 5.16 The Italian Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 5.17 The Spanish Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 5.18 The Spanish Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 5.19 The Japanese Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 5.20 The Japanese Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 5.21 The Brazilian Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 5.22 The Brazilian Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 5.23 The Russian Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 5.24 The Russian Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 5.25 The Indian Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 5.26 The Indian Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 5.27 The Chinese Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2011-2017
Table 5.28 The Chinese Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2017-2023
Table 6.1 Drug Discovery Outsourcing: SWOT Analysis, 2013-2023
Table 6.2 NIH Biomarker Definitions, 2012
Table 8.1 Global Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2011-2023

List Of Figures

LIST OF FIGURES

Figure 2.1 Selected Tasks Outsourced in the Pharmaceutical Industry, 2012
Figure 2.2 Typical Stages of the Drug Development Cycle
Figure 3.1 AMRI Revenue ($m), 2007-2011
Figure 3.2 Charles River Laboratories Revenue ($bn), 2006-2011
Figure 3.3 Charles River Laboratories Revenue (%) by Business Segment, 2011
Figure 3.4 Covance Revenue (%) by Segment, 2011
Figure 3.5 Covance Revenue ($bn) by Service, 2009-2011
Figure 3.6 Cyprotex Revenue ($m), 2009-2011
Figure 3.7 Evotec Revenue ($m) and Alliances, 2008-2011
Figure 3.8 Evotec Regional Revenue Share (%), 2011
Figure 3.9 Galapagos Revenue ($m), 2008-2011
Figure 3.10 Galapagos Revenue (%) by Segment, 2011
Figure 3.11 PPD Revenue ($bn), 2009-2011
Figure 3.12 WuXi AppTec Revenue ($bn), 2006-2011
Figure 4.1 Global Drug Discovery Outsourcing Revenue Forecast ($m), 2011-2017
Figure 4.2 Global Drug Discovery Outsourcing Revenue Forecast ($m), 2017-2023
Figure 4.3 Drug Discovery Outsourcing: World Market Shares by Segment (%), 2011
Figure 4.4 Drug Discovery Outsourcing: World Market Shares by Segment (%), 2017
Figure 4.5 Drug Discovery Outsourcing: World Market Shares by Segment (%), 2023
Figure 4.6 Chemistry Services Revenue Forecast ($m), 2011-2017
Figure 4.7 Chemistry Services Revenue Forecast ($m), 2017-2023
Figure 4.8 Biology Services Revenue Forecast ($m), 2011-2017
Figure 4.9 Biology Services Revenue Forecast ($m), 2017-2023
Figure 4.10 Lead Optimisation Revenue Forecast ($m), 2011-2017
Figure 4.11 Lead Optimisation Revenue Forecast ($m), 2017-2023
Figure 4.12 Lead Identification and Screening Revenue Forecast ($m), 2011-2017
Figure 4.13 Lead Identification and Screening Revenue Forecast ($m), 2017-2023
Figure 5.1 Drug Discovery Outsourcing: World Market Shares by Region (%), 2011
Figure 5.2 Drug Discovery Outsourcing: World Market Shares by Region (%), 2017
Figure 5.3 Drug Discovery Outsourcing: World Market Shares by Region (%), 2023
Figure 5.4 The US Drug Discovery Outsourcing Forecast ($m), 2011-2023
Figure 5.5 The EU5 Drug Discovery Outsourcing Forecast ($m), 2011-2023
Figure 5.6 Drug Discovery Outsourcing: EU5 Market Shares by Country (%), 2011
Figure 5.7 The German Drug Discovery Outsourcing Forecast ($m), 2011-2023
Figure 5.8 The UK Drug Discovery Outsourcing Forecast ($m), 2011-2023
Figure 5.9 The French Drug Discovery Outsourcing Forecast ($m), 2011-2023
Figure 5.10 The Italian Drug Discovery Outsourcing Forecast ($m), 2011-2023
Figure 5.11 The Spanish Drug Discovery Outsourcing Forecast ($m), 2011-2023
Figure 5.12 The Japanese Drug Discovery Outsourcing Forecast ($m), 2011-2023
Figure 5.13 The Brazilian Drug Discovery Outsourcing Forecast ($m), 2011-2023
Figure 5.14 The Russian Drug Discovery Outsourcing Forecast ($m), 2011-2023
Figure 5.15 The Indian Drug Discovery Outsourcing Forecast ($m), 2011-2023
Figure 5.16 The Chinese Drug Discovery Outsourcing Forecast ($m), 2011-2023
Figure 6.1 Drug Discovery Outsourcing: Drivers, 2013-2023
Figure 6.2 Drug Discovery Outsourcing: Restraints, 2013-2023
Figure 8.1 Global Drug Discovery Outsourcing Forecast by Segment ($m), 2011-2023

COMPANIES LISTED

Abbott
AbCRO
Accugenix
Advion Bioanalytical Labs
Advion BioService
Albany Molecular Research, Inc (AMRI)
American Cancer Society
Andromeda Biotech
Apredica
Aptuit
Aptuit Laurus
Argenta
Ark Therapeutics
ArQule
Associaчуo Brasileira de CROs (Abracro)
AstraZeneca
Bayer
Behrman Capital
Beijing Genomics Institute
BioDuro
BioDuro Biologics
BioFocus
BioPontis Alliance
Boehringer Ingelheim
Boston College
Bristol-Myers Squibb
Bundesverband Medizinischer Auftragsinstitute (BVMA)
Caprion Proteomics
Carlyle Group
Catalent Pharma Solutions
Cerebricon
Charles River Laboratories
CHDI Foundation
ChemBridge
ChemDiv
Compound Focus
Covance
CreaGen Biosciences
Crucell
Cyprotex
DeveloGen
Discovery Partners International
Domainex
Dow AgroSciences
Dow Chemical Company
Elan
Eli Lilly
Evotec
Evotec BioSystems AG
Excel PharmaStudies
Fidelity Growth Partners India (FGPI)
Food and Drug Administration (US FDA)
Furiex Pharmaceuticals
Galapagos
Genentech
GenScript
GlaxoSmithKline (GSK)
Glycoform
Great Lakes Chemical Corporation
Harvard Medical School
Hellman & Friedman
Horizon
Hypha Discovery
ICON
Inpharmatica
InSphero
InVentiv Health
Johnson & Johnson (J&J)
Janssen Pharmaceutica
Janssen Pharmaceutical Group
Kinaxo
Knopp Biosciences
Laurus Labs
Lonza
MAB Discovery
Massachusetts General Hospital
MedImmune
Merck & Co.
Microsoft
Midwest BioResearch
Millipore
National Institutes of Health (NIH)
Northeastern University
Novartis
Ono Pharmaceutical
Oxford Asymmetry International
Parexel
Peking Union Lawke Biomedical Development
Pfizer
Pharmaceutical Product Development (PPD)
Pharmaceutical Research and Manufacturers of America (PhRMA)
Pharminox
Piedmont Research Center
PPD
PRA International
ProSkelia
ProStrakan
Proteome Sciences
Proteros Biostructutres GmbH (Proteros)
ProtonMedia
Quintiles
Roche
Rules-Based Medicine (RBM)
Samsung
Sanofi
Sareum
Servier
Shionogi
Sirius Analytical
Solvo Biotechnology
Southwestern Medical Center
Swiss Pharma Contract
Sygnature Discovery
SYN|thesis Med Chem
Taijitu Biologics
Takeda
Teva
The Dow Chemical Company
The European CRO Federation (EUCROF)
The Institute of Cancer Research
The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)
The Organization for Economic Cooperation and Development (OECD)
Tibotec
TRAC Microbiology
TransGenic
UCB
University of Manchester
VitualScopics
Wellcome Trust
WIL Research Laboratories
World Health Information Science Consultants (WHISCON)
World Health Organization (WHO)
World Trade Organization (WTO)
WuXi AppTec
WuXi PharmaTech